MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Phase 4
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Interferon beta-1a (Rebif)
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 30
- Registration Number
- NCT01142466
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 403
- Registration Number
- NCT01142492
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 86
- Registration Number
- NCT01142518
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 522
- Registration Number
- NCT01142557
- Locations
- 🇩🇪
Merck Serono GmbH, Darmstadt, Germany
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Terminated
- Conditions
- Carcinoma, Squamous Cell
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 133
- Registration Number
- NCT01142869
- Locations
- 🇮🇳
Bhagwan Mahaveer Cancer Hospital, Jaipur, Rajasthan, India
🇮🇳Dr. Vineet's Clinic, New Delhi, Uttar Pradesh, India
🇮🇳Galaxy Care Laproscopic Institute, Pune, Maharashtra, India
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 192
- Registration Number
- NCT01142583
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
Completed
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 231
- Registration Number
- NCT01142453
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 334
- Registration Number
- NCT01141751
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
Completed
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 286
- Registration Number
- NCT01134640
- Locations
- 🇨🇳
Chi Mei Medical Center, Yongkang, Tainan, Taiwan
🇨🇳Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
🇨🇳Buddhist Tzu Chi General Hospital, Taipei, Taiwan
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
Phase 2
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 305
- Registration Number
- NCT01134627
- Locations
- 🇩🇰
Scleroseklinikken afsnit 2082, Copenhagen, Denmark
© Copyright 2025. All Rights Reserved by MedPath